A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.

[1]  Hiroshi Yamamoto,et al.  An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease , 2020, Medicine.

[2]  Hiroshi Yamamoto,et al.  Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease , 2020, Medicine.

[3]  M. Betts,et al.  Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. , 2020, JCI insight.

[4]  G. Wertheim,et al.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. , 2019, The Journal of clinical investigation.

[5]  K. Shiozawa,et al.  Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan , 2018, Modern rheumatology.

[6]  M. Kojima,et al.  Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012 , 2013, Journal of clinical and experimental hematopathology : JCEH.

[7]  E. Bartoli,et al.  Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. , 1980, American journal of clinical pathology.

[8]  B. Castleman,et al.  Localized mediastinal lymph‐node hyperplasia resembling thymoma , 1956, Cancer.